About Us
Company Overview
Photo of man in lab


Eureka Therapeutics, Inc. is a privately-owned, venture capital-funded biotechnology company headquartered in Emeryville, California. Our main focus is the development of therapeutic monoclonal antibodies for cancer indication and treatment. In addition, Eureka provides a range of services to partner companies pursuing therapeutic antibody treatments for disease.

Our primary technology involves the enhancement of the ADCC activity of human (or humanized) antibodies to improve their clinical efficacy. Currently, Eureka has one US research facility dedicated to technology innovation and service provision, and one Chinese subsidiary in Beijing for carrying out preclinical and clinical studies.
divLine_1

Corporate Team

Photo of Cheng Liu
Cheng Liu
Founder & CEO
Dr. Liu is the founder and CEO of Eureka Therapeutics, Inc. Prior to founding Eureka, Dr. Liu served as a principal scientist in the Preclinical Research Department at Chiron. Dr. Liu has close to 20 years of experience in biology research and drug discovery with extensive experience and knowledge in drug targeting, validation, assay development, and screening for therapeutic protein drug discovery. Dr. Liu has extensive experience and knowledge in cancer target discovery and validation, assay development, and high throughput screening for therapeutic protein and antibody drug discovery. He is the inventor of 14 patents filed in the US and Europe. He served as president of SAPA-West from 1998-2000 and VP of SAPA (Sino-American Pharmaceutical Professionals Association) from 1996-1997.

Dr. Liu received his B.S. in Genetics from Beijing University, M.S. in Molecular Biology from Beijing University, and a Ph.D. in Cell Biology from the University of California, Berkeley.
divLine_2

Photo of Wai-Yan Sandy Chau
Wai-Yan Sandy Chau
Chairman, Board of Directors
Wai-Yan Sandy Chau is both Founder and President of Trident USA: a diversified holding company that invests in real estate and provides venture capital throughout Greater China and the United States. As a Hua Yuan "Angel," Mr. Chau has been an active investor in several companies started by Hua Yuan members including: Achievo, Viador, Servgate, Photonify, EnReach, and Televigation. Prior to Trident USA, from 1986 - 1999 Mr. Chau actively invested in real estate and provided venture capital in Taiwan, China, and the US. He served as Chairman of CITIC Shenzhen Properties from 1994 - 1997 and from 1992 - 1995 served as President of Pacific Constructions, one of the largest public real estate development companies traded publicly in Taiwan. Before real estate, Mr. Chau was a successful technology entrepreneur, founding Universal Semiconductor and running the company as its CEO. Mr. Chau was born in Shanghai, was raised in Hong Kong and Vietnam, and received his B.S. and MBA in the US.
divLine_2

Photo of Bruce Ames, Ph.D.
Bruce Ames, Ph.D.
Chairman of Scientific Advisory Board
Dr. Ames is a Professor of Biochemistry and Molecular Biology, University of California, Berkeley. Dr. Ames is well-known for his invention of the Ames Test, a biological assay to assess the mutagenic potential of chemical compounds. He currently serves on the Commission on Life Sciences for the National Academy of Sciences and was a member of the board of directors of the National Cancer Institute from 1976 to 1982. He was the recipient of the General Motors Cancer Research Foundation Prize (1983), the Tyler Environmental Prize (1985), the Gold Medal Award of the American Institute of Chemists (1991), the Glenn Foundation Award of the Gerontological Society of America (1992), the Lovelace Institutes Award for Excellence in Environmental Health Research (1995), the Honda Prize of the Honda Foundation, Japan (1996), the Japan Prize awarded by the Japanese Emperor , (1997), the Kehoe Award, American College of Occupational And Environmental Medicine (1997), the Medal of the City of Paris (1998), the U.S. National Medal of Science awarded by President Clinton(1998), the Linus Pauling Institute Prize for Health Research (2001), and the American Society for Microbiology Lifetime Achievement Award (2001). He has contributed to over 450 publications and is one of the most-cited scientists in all fields.
divLine_2

Photo of Hsing-Jien Kung, Ph.D.
Hsing-Jien Kung, Ph.D.
Board Member, and Scientific Advisory Board Member
Dr. Kung is a Professor in Biological Chemistry at the University of California at Davis, School of Medicine. He is also the Director of Basic Science Research at the UC Davis Cancer Center. Dr. Kung is an internationally known scientist and cancer researcher. His current major research interests include signal transduction, oncogenes, tyrosine kinases, prostate cancer and cancer virology. Dr. Kung earned his Ph.D. from the California Institute of Technology in 1976, and his B.S. in Chemistry from the National Taiwan University in 1969.divLine_2

Photo of Peter Lee, M.D.
Peter Lee, M.D.
Scientific Advisory Board Member
Dr. Lee is an Assistant Professor in Medicine (hematology) and a member of the Comprehensive Cancer Center at Stanford University. His research focuses on understanding the biology of the immune response to cancer. Dr. Lee’Äôs research seeks to establish how the immune system distinguishes between a normal cell and a cancer cell, the molecular mechanisms by which cancer cells modulate the immune response, and how different treatments (e.g. chemotherapy, radiation, transplantation, biotherapies, etc.) - impact the balance between tumor cell proliferation and the immune response. Dr. Lee was the recipient of the Era of Hope Award for breast cancer research in 2006.
divLine_2

John Curd, M.D.
Scientific Advisory Board Member
Dr. Curd is President and Chief Medical Officer of Novacea. From June 1999 to May 2001, Dr. Curd served as Executive Vice President at VaxGen, Inc., a vaccine company. From December 1991 to June 1999, Dr. Curd served in various positions, including Vice President of Clinical Development at Genentech. While at Genentech, he directed the clinical development of Herceptin¬Æ, Rituxan¬Æ, Xolair’Ñ¢ and Raptiva’Ñ¢. From 1978 to 1991, Dr. Curd served in various positions, including President of the Medical Staff at Scripps Clinical and Research Foundation, La Jolla, California. Dr. Curd holds a B.S. in chemistry from Princeton University and an M.D. from Harvard Medical School.
divLine_2

Wei Zhou, Ph.D., J.D.
Scientific Advisory Board Member


no text here yet...